how can mutational screening guide current clinical practice in mds?
Published 2 years ago • 44 plays • Length 2:48Download video MP4
Download video MP3
Similar videos
-
3:10
how mutation screening impacts transplant decisions in mds
-
2:45
an insight into clinical risk factors for progression in mpns
-
5:38
the molecular and clinical classifications of mds
-
3:19
key clinical trials in mds taking place in the us
-
4:28
current and emerging treatment options for mds
-
6:11
sophia’s ihope story: diagnosing a rare de novo mutation
-
5:37
how-to | detect a diseased eye (studio 5)
-
50:56
chip and ccus, precursors to mds
-
2:16
current and future treatment approaches for hr-mds
-
3:08
htert reduction by imetelstat correlates with clinical activity in mds
-
1:36
clinical trials evaluating novel agents in mds: select-mds-1
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve
-
1:41
an overview of the mds diagnosis pathway
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
2:48
developing effective methods to study qol in clinical trials in mds
-
3:01
challenges in distinguishing between pre-mds states and mds, and approaches to improve diagnosis
-
1:18
incorporating genetic analyses in the diagnostic pathway of mds
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
1:06
the current state of the art in hr-mds and the need to improve treatment approaches
-
1:45
challenges in mm guideline implementation
-
1:04
the future of mds management
-
3:10
the role of ngs in mds diagnosis